Result for
Topic: Vaccines and Immunity
April 30, 2021
Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021
A review of post-authorization safety data after administration of 7.98 million doses of Johnson & Johnson/Janssen COVID-19 vaccine during March–April 2021 found that commonly-reported reactions, such as fatigue and pain, were similar to those observed in clinical trials, and 97% of these events were classified as nonserious. A total of 17 events consistent with cerebral…
Previously Infected Vaccinees Broadly Neutralize SARS-CoV-2 Variants
[Pre-print, not peer-reviewed] A small study of sera from patients vaccinated with the Pfizer-BioNTech vaccine (N=30) found similar levels of anti-SARS-CoV-2 spike antibodies in persons with and without previous documentation of SARS-CoV-2 infection. Additionally, post-vaccination sera from previously infected persons demonstrated higher neutralizing activity in in-vitro against B.1.1.7, B.1.351 and P.1 compared to previously uninfected…
Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021
A review of data from 5 mass vaccination sites providing the Johnson & Johnson/Janssen COVID-19 vaccine (total doses=8,624) revealed 64 anxiety-related events post-vaccination, including 17 events of fainting. The most commonly-reported event was light-headedness or dizziness. 13 persons were transported to an emergency department for follow-up, and all five for whom follow-up information was available…
Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials
A meta-analysis of efficacy data from Phase III trials of the Pfizer-BioNTech, Moderna, AstraZeneca, and Sputnik V vaccines found that type of vaccine, age and sex of recipients, and the underlying rate of COVID-19 in the study populations did not affect vaccine efficacy. The meta-regression calculated lower efficacy point estimates for the mRNA vaccines among…
April 29, 2021
Prothrombotic Immune Thrombocytopenia after COVID-19 Vaccine
5 cases of prothrombotic immune thrombocytopenia were identified in Germany at 5 to 11 days after receiving the first dose of the Oxford-AstraZeneca vaccine. Clinical manifestations included cerebral venous sinus thrombosis, splanchnic vein thrombosis, arterial cerebral thromboembolism, and thrombotic microangiopathy. Anti-PF4/polyanion antibodies were detected in all patients. After anticoagulation alone or in combination with eculizumab…
Antibody Response to Coronavirus Disease 2019 (COVID-19) Messenger RNA Vaccination in Pregnant Women and Transplacental Passage Into Cord Blood
Among 122 pregnant women who delivered on or after 35 weeks gestation and received a COVID-19 mRNA vaccine by the time of delivery (n= 55 first dose, n=67 both doses), anti-SARS-CoV-2 IgG antibodies were detected in maternal blood as early as 5 days and in cord blood as early as 16 days after the first…
Maternal Antibody Response, Neutralizing Potency, and Placental Antibody Transfer After Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection
Among maternal blood samples from SARS-CoV-2 positive patients obtained after delivery (n=32), higher median anti-RBD IgG titers were significantly associated with symptomatic (vs. asymptomatic) infection but not with having a PCR-positive test more than 14 days earlier (vs. PCR-positive test within 14 days). Paired cord blood samples also obtained after delivery show that median cord/maternal…
April 28, 2021
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged =65 Years — United States, January–March 2021
Among adults age 65 and older (n = 417), mRNA vaccines were 94% effective against hospitalization for COVID-19 among fully vaccinated individuals, and 64% effective among partially-vaccinated individuals, according to data from US hospitals during January-March 2021. In the study, Pfizer and Moderna vaccines were equally represented, and approximately half of participants were over the…
Association of Facial Paralysis With MRNA COVID-19 Vaccines
There was no evidence for an association between facial paralysis and mRNA vaccines for SARS-CoV-2 compared to other vaccines, according to a study using World Health Organization data. Among 133,883 cases of adverse drug reactions reported with mRNA vaccines, 844 (0.6%) total facial paralysis-related events were identified, 749 of which were reported with the Pfizer-BioNTech…
Safety and Immunogenicity of One versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients with Cancer: Interim Analysis of a Prospective Observational Study
Among patients with cancer, one dose of the Pfizer-BioNTech vaccine did not elicit a strong antibody response. In a prospective observational study, the proportion of positive anti-S IgG titers measured at 21 days after vaccination was 38% among patients with solid cancers (21/56 patients), 18% among patients with hematological cancer (8/44), and 94% (32/34) among…
Previous page Next page